Company Profile
Amylyx Stock Price, News & Catalysts
- Ticker:
- AMLX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
28.08 USD (-3.51%)
Close
Last updated: October 1, 2026
1.48B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, AMLX closed down 3.51% at $28.08. No new same-company headline was identified in the current news window.
Company overview
Neuroendocrine and Rare-Disease Biotechnology Company
Amylyx Pharmaceuticals develops therapies for endocrine and neurological diseases with limited treatment options. Its portfolio combines peptide therapeutics, antisense oligonucleotides, and small-molecule approaches across post-bariatric hypoglycemia, amyotrophic lateral sclerosis, Wolfram syndrome, and related disorders.
Avexitide and Post-Bariatric Hypoglycemia
Avexitide is a GLP-1 receptor antagonist designed to reduce the excessive insulin response that drives post-bariatric hypoglycemia. It is the company's lead late-stage asset and has received Breakthrough Therapy designation for both post-bariatric hypoglycemia and congenital hyperinsulinism.
Neurology Programs
AMX0114 is an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis. The program is in first-in-human development and reflects Amylyx's effort to build a mechanistically differentiated neurology pipeline beyond its earlier commercial history.
Wolfram Syndrome Development
AMX0035 is being studied in Wolfram syndrome, a rare genetic disorder affecting pancreatic beta cells, vision, and neurological function. Open-label clinical findings have supported continued discussions with the FDA regarding a potential Phase 3 study.
Next-Generation Endocrine Pipeline
AMX0318 is a long-acting GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia and other rare endocrine diseases. Amylyx is using external research collaborations to identify additional peptide candidates and broaden its endocrine portfolio.
Future catalysts
- Topline Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia in late August or early September 2026.
- Potential avexitide NDA submission and commercial launch in 2027, subject to positive data and regulatory review.
- IND filing for long-acting GLP-1 receptor antagonist AMX0318 in 2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amylyx (AMLX)?
Amylyx (AMLX) most recently closed at 28.08 USD, a -3.51% move versus the previous session.
What is the market cap of Amylyx (AMLX)?
Amylyx currently has a market capitalization of 1.48B USD on BioPharmSignal.
What does Amylyx do?
Neuroendocrine and Rare-Disease Biotechnology Company Amylyx Pharmaceuticals develops therapies for endocrine and neurological diseases with limited treatment options. Its portfolio combines peptide therapeutics, antisense oligonucleotides, and small-molecule approaches across post-bariatric hypoglycemia, amyotrophic lateral sclerosis, Wolfram syndrome, and...
On which exchange is AMLX stock listed?
Amylyx (AMLX) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
IND filing for long-acting GLP-1 receptor antagonist AMX0318 in 2027.
Which conditions is Amylyx targeting with GLP-1?
Amylyx is associated with neurology, genetic disease based on its company overview and current catalyst commentary.
How does Amylyx describe recent progress with GLP-1?
IND filing for long-acting GLP-1 receptor antagonist AMX0318 in 2027.
What is Neuroendocrine?
Neuroendocrine and Rare-Disease Biotechnology Company Amylyx Pharmaceuticals develops therapies for endocrine and neurological diseases with limited treatment options.